Andy Batts
Long only, value, growth, momentum

Abaxis: Buying Opportunity Amid Correction With Significant Upside

Union City, California, -based Abaxis (NASDAQ:ABAX), a company that manufactures and sells portable blood analysis systems for human and veterinary uses, has seen its stock corrected almost 25% from the top it created at $51.84 in July. Currently the stock is consolidating around $40 and looks dirt-cheap post correction. In this investment thesis I will explain why investors should consider accumulating the stock in this corrective phase. I expect the stock to rise ~50% from the current level over the next 12 months, against a very limited downside of not more than 5%.

Company Overview

Abaxis is famous for its blood constituent measurement devices. Its point-of-care blood chemistry analyzer systems are used extensively in human medical and veterinary

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details